Research programme: Proto oncogene proteins c-akt inhibitors - Novelion Therapeutics

Drug Profile

Research programme: Proto oncogene proteins c-akt inhibitors - Novelion Therapeutics

Alternative Names: KP372-1; Research programme: PKB inhibitors - Kinetek

Latest Information Update: 30 Nov 2016

Price : $50

At a glance

  • Originator QLT
  • Class Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 29 Nov 2016 QLT acquired Aegerion Pharmaceuticals and later QLT changed its name to Novelion Therapeutics
  • 18 Jan 2006 A preclinical study has been added to the Cancer pharmacodynamics section
  • 01 Jul 2004 Kinetek Pharmaceuticals has been acquired and merged into QLT
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top